Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes

• Published in: Life sciences (1973) Vol. 231; p. 116577
• Main Authors: Atalar, Mehmet Nuri, Abuşoğlu, Sedat, Ünlü, Ali, Tok, Oğuzhan, İpekçi, Süleyman Hilmi, Baldane, Süleyman, Kebapcılar, Levent
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 15.08.2019; Elsevier BV
• Subjects: Adult; Arginine; Arginine - blood; Biomarkers - blood; blood glucose; Blood Glucose - metabolism; blood serum; C-Reactive Protein - metabolism; Chemiluminescence; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Fasting - blood; Female; Fibrosis; Galectin 3 - analysis; Galectin 3 - blood; Galectin-3; galectins; Glucose; Glucose tolerance; Glucose Tolerance Test; glucose tolerance tests; Glycated Hemoglobin A - metabolism; Humans; Immunoassay; immunoassays; inflammation; Insulin Resistance; Male; Mass spectrometry; Mass spectroscopy; Methylated arginines; Methylation; Microparticles; Middle Aged; Neopterin; noninsulin-dependent diabetes mellitus; Organic chemistry; patients; Prediabetes; Prediabetic State - blood; tandem mass spectrometry; Type 2 diabetes; Type 2 diabetes; Galectin-3; Prediabetes; Methylated arginines
• ISSN: 0024-3205; 1879-0631; 1879-0631
• DOI: 10.1016/j.lfs.2019.116577

Galectin-3 is associated with the process of inflammation and fibrosis. The aim of this study was both to evaluate of galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes and to investigate a relation between serum galectin-3, methylated arginines and hs-CRP levels. In this study, all subjects were defined as the control group, type 2 diabetes (n = 84) by fasting plasma glucose and prediabetes (n = 34) by 75-g oral glucose tolerance test. Also, participants with type 2 diabetes were divided into as group I (HbA1c ≤7%, n = 40) and group II (HbA1c ≥7%, n = 44). The analysis of serum methylated arginines levels was analyzed by tandem mass spectrometry. Galectin-3 levels were determined via chemiluminescent microparticle immunoassay (CMIA). Serum galectin-3, ADMA, L-NMMA and SDMA levels were significantly lower in the control group (13.3 ± 3.42; 0.630 (0.13–1.36); 0.176 (0.02–0.53); 0.115 (0.04–0.26), respectively) compared to diabetic subjects (15.71 ± 4.22; 0.825 (0.23–2.80); 0.366 (0.08–1.41); 0.1645 (0.06–0.47), p = 0.002, p = 0.01, p = 0.001 and p = 0.006, respectively). Galectin-3 was positively correlated with hs-CRP (r = 0.295 p = 0.001), L-NMMA (r = 0.181 p = 0.022), HbA1c (r = 0.247 p = 0.002), neopterin (r = 0.160 p = 0.045) and FPG (r = 0.207 p = 0.001) respectively. Also, there was positively correlated ADMA with FPG (r = 0.192 p = 0.016) and eAG (r = 0.235 p = 0.003). Thus, galectin-3 might be a useful prognostic marker in the population with prediabetes and diabetes. Moreover, it can be a marker showing the condition of developing complications in diabetic patients. •Galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes•The levels of these biomarkers were found higher in participants with type 2 diabetes.•The levels of these molecules may be used to identify the subjects predisposed to diabetes.